First Tracks Biotherapeutics reports Q3 2026 loss narrowing and advances ANB033 program

First Tracks Biotherapeutics announced a net loss of $31.4 million for the quarter ended September 30, 2026, an improvement of 25.1% from the same quarter a year earlier, with diluted loss per share of $0.88. The company highlighted positive Phase 1b data for ANB033 in celiac disease and ongoing trials in eosinophilic esophagitis, while rosnilimab showed continued efficacy in rheumatoid arthritis. Cash and equivalents stood at $155.6 million, rising to approximately $343 million on a pro‑forma basis after a $200 million private placement. Management indicated that top‑line data from ANB033 trials are expected in early 2027.

The narrower loss and strong cash position extend the company’s runway, reducing short‑term financing risk. Upcoming clinical readouts could materially affect the valuation of the company’s pipeline assets.

  • 1Net loss was $31.4 million for Q3 2026, compared with $41.9 million in the prior-year quarter, a 25.1% year‑over‑year improvement.
  • 2Diluted loss per share narrowed to $0.88 from $1.50 a year earlier, a 41.3% reduction.
  • 3Phase 1b gluten‑challenge data for ANB033 in celiac disease showed significant improvements versus placebo with no serious adverse events.
  • 4Phase 2b rheumatoid arthritis results for rosnilimab demonstrated improvements across disease measures that persisted after treatment ended.
  • 5Cash, cash equivalents and investments were $155.6 million as of September 30, 2026.
  • 6Pro‑forma cash totalled approximately $343 million after a $200 million private placement completed in October 2026.

Sources